In a step toward treating mitochondrial diseases, researchers in the Netherlands have successfully edited harmful mutations ...

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

They also found that after the extra chromosome was removed, genes tied to nervous system development were more active and ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

The duration of expression of the gene Cdx2 is tightly regulated by a newly identified DNA sequence element called an ...

CRISPR Therapeutics (NASDAQ:CRSP) operates within the biotechnology segment, which remains active across key indices like the ...

Precision gene editing is crucial for treating genetic diseases, as it enables targeted correction of specific mutations. A Korean research team has become the first in the world to significantly ...

A team at Kobe University has created a game-changing resource for autism research: 63 mouse embryonic stem cell lines, each ...

Brian Armstrong, the billionaire CEO of the cryptocurrency exchange Coinbase, says he’s ready to fund a US startup focused on ...

Amid a challenging gene editing climate, partnerships between researchers, regulators, and industry remain crucial for ...